Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul 9;9:1568.
doi: 10.3389/fimmu.2018.01568. eCollection 2018.

A Review of DNA Vaccines Against Influenza

Affiliations
Free PMC article
Review

A Review of DNA Vaccines Against Influenza

Leo Yi Yang Lee et al. Front Immunol. .
Free PMC article

Abstract

The challenges of effective vaccination against influenza are gaining more mainstream attention, as recent influenza seasons have reported low efficacy in annual vaccination programs worldwide. Combined with the potential emergence of novel influenza viruses resulting in a pandemic, the need for effective alternatives to egg-produced conventional vaccines has been made increasingly clear. DNA vaccines against influenza have been in development since the 1990s, but the initial excitement over success in murine model trials has been tempered by comparatively poor performance in larger animal models. In the intervening years, much progress has been made to refine the DNA vaccine platform-the rational design of antigens and expression vectors, the development of novel vaccine adjuvants, and the employment of innovative gene delivery methods. This review discusses how these advances have been applied in recent efforts to develop an effective influenza DNA vaccine.

Keywords: DNA vaccine; adjuvant; hemagglutinin; immunization; influenza.

Figures

Figure 1
Figure 1
Key factors considered in the design, formulation, and inoculation of DNA vaccines to improve in vivo transfection efficiency and antigen immunogenicity.

Similar articles

See all similar articles

Cited by 4 articles

References

    1. WHO. Influenza (Seasonal) – Fact Sheet. Geneva: World Health Organisation Media Centre; (2018). Available from: http://www.who.int/mediacentre/factsheets/fs211/en/ (Accessed: April 17, 2018).
    1. Sullivan SG, Chilver MB, Carville KS, Deng YM, Grant KA, Higgins G, et al. Low interim influenza vaccine effectiveness, Australia, 1 May to 24 September 2017. Euro Surveill (2017) 22(43):17-00707.10.2807/1560-7917.ES.2017.22.43.17-00707 - DOI - PMC - PubMed
    1. Flannery B, Chung JR, Belongia EA, Mclean HQ, Gaglani M, Murthy K, et al. Interim estimates of 2017–18 seasonal influenza vaccine effectiveness – United States, February 2018. MMWR Morb Mortal Wkly Rep (2018) 67:180–5.10.15585/mmwr.mm6706a2 - DOI - PMC - PubMed
    1. Dos Santos G, Neumeier E, Bekkat-Berkani R. Influenza: can we cope better with the unpredictable? Hum Vaccin Immunother (2016) 12:699–708.10.1080/21645515.2015.1086047 - DOI - PMC - PubMed
    1. Bruffaerts N, Huygen K, Romano M. DNA vaccines against tuberculosis. Expert Opin Biol Ther (2014) 14:1801–13.10.1517/14712598.2014.951630 - DOI - PubMed

LinkOut - more resources

Feedback